EvolveImmune Therapeutics

#EvolveImmune welcomed back co-founder Charles Fuchs, MD, MPH for a seminar and Fireside Chat focused on leadership, innovation, and lessons from his distinguished career in medicine.   His reflections offered a unique perspective shaped by experience across patient care, research, and executive leadership, and many impactful personal reflections.   Thank you Charles Fuchs for sharing your experiences and for an inspiring conversation with our team. #ForPatients #Innovation #PatientJourney #TeamScience

Congratulations to our team members who graduated from the University of New Haven this past weekend! Andrew Keane – Intern, Translational Sciences Emma Lewko – Research Associate, Translational Sciences Jeremy Wilson – Research Associate, Biotherapeutics We are proud to celebrate this accomplishment and recognize the hard work and commitment each of you has shown along the way. Wishing you continued success in all that’s ahead. #EvolveImmune #ForPatients #Graduation

What a great response at #PEGS2026 to our latest #EvolveImmune updates! Thank you to everyone who attended and engaged with our presentation and latest technology advances. It was a pleasure connecting with collaborators and innovators across the field. #ForPatients #CD2 #TeamScience #Immunotherapy #Biotech #TCellEngagers #CancerResearch #Conference #Research

We're #hiring for two openings! We're seeking a Scientist/Senior Scientist, Translational Sciences and a Principal Scientist, Antibody Discovery/Protein Design.   If you’re someone who enjoys hands-on science, collaboration, and helping drive new discoveries in immunotherapy, this could be a great fit. Apply today or share this post with your network. #EvolveImmune #AntibodyDiscovery #ProtienDesign #DrugDiscovery #Biotherapeutics #TranslationalScience #NextGenImmunotherapy   https://lnkd.in/ewQZSwsf   https://lnkd.in/eHTYWz7G

#EvolveImmune will be at #PEGS2026! Join Jeremy Myers, Ph.D. as he presents "EVOLVE: T Cell Engager Designs to Maximize Tumor Engagement with Integrated CD2 Costimulation" on May 12, 2026, at 3:00 p.m. ET. We look forward to sharing our latest advances! #EVOLVE #ForPatients #TeamScience #Conference #Research #Innovation

May is Bladder Cancer Awareness Month. #EvolveImmune is committed to delivering innovative solutions and better outcomes for patients and their families. #BladderCancer #ForPatients #TeamScience

#EvolveImmune is grateful to be highlighted in the Biotech Strategy Blog. We appreciate the dive deep into the science that sets our #EVOLVE platform apart from first‑generation TCEs. Thank you to Sally Church for the thoughtful perspective and for helping to share our progress with the broader IO community. #CD2 #ForPatients

 #EvolveImmune is pleased to nominate and advance the first development candidate from our collaboration with our AbbVie partners. The achievement of this milestone underscores the ability of our #EVOLVE platform to deliver innovative T cell engagers with the potential to address key unmet medical needs in #oncology. Kudos to our tremendous team on this important accomplishment. #ForPatients #TeamScience #CD2 https://lnkd.in/egqVYjqJ

We’re incredibly grateful for the strong interest in our progress at #AACR2026 and the opportunity to engage with so many across the scientific and biotech community. Sharing #EvolveImmune’s story and approach was both energizing and inspiring as we continue to advance our work. #EVOLVE104 #ForPatients #TeamScience https://lnkd.in/eTG8YH3u

We’re incredibly grateful for the strong interest in our progress at #AACR2026 and the opportunity to engage with so many across the scientific and biotech community. Sharing #EvolveImmune’s story and approach was both energizing and inspiring as we continue to advance our work. #EVOLVE104 #ForPatients #TeamScience https://lnkd.in/eTG8YH3u